SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported)       APRIL 19, 1996

                              ENZON, INC.

          (Exact  name  of  registrant  as  specified in its charter)




       DELAWARE                    0-12957              22-237286
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)


        20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (908) 980-4500




     (Former name or former address, if changed since last report)










ITEM 5.  OTHER EVENTS

          On April 19, 1996, the Board of Directors (the "Board") of Enzon,
Inc. ("Enzon" or the "Company") elected Randy H. Thurman as Chairman of the
Company's Board of Directors.

          Mr. Thurman has been a director of Enzon since 1993.  He replaces
Dr. Abraham Abuchowski, a co-founder and/or director of Enzon since 1983.

          Mr.  Thurman  most  recently  was  Chairman  and Chief  Executive
Officer  of  Corning  Life Sciences, a diversified health services  company
specializing in contract  pharmaceutical research and commercial laboratory
testing.  Previously, Mr. Thurman  was  President  of  Rhone-Poulenc  Rorer
Pharmaceuticals.   He  is  also  the  founder  and  Chairman of Health Care
Strategies 2000, a global healthcare consulting company  focusing on health
care strategy.

          Mr.  Thurman  will  serve  in  a  non-executive role and  provide
strategic  guidance  and  assist  in  building relationships  with  leading
companies and institutions.

          The  Company  also  formed a Research  and  Development  Steering
Committee which will direct the  overall  Research and Development strategy
reporting to Mr. Tombros.  Joining Mr. Tombros on the Steering Committee is
Rosina B. Dixon, M.D., who previously held senior positions in Research and
Development with Ciba-Geigy and Schering-Plough.   Dr.  Dixon is a director
of  Enzon.   Richard Cooper, M.D., Chairman of Enzon's Scientific  Advisory
Committee, Director  of  the  Medical  College  of  Wisconsin Health Policy
Institute and retired Dean of the Medical College of  Wisconsin  will  also
serve  on the Steering Committee, along with Dr. Robert Shorr, Enzon's vice
president of Research and Development.  Dr. Abuchowski has relinquished all
of his responsibilities  as  an employee of Enzon and has resigned from the
Board of Directors.

          On April 19, the Company  received  an inquiry from Nasdaq Market
Surveillance  regarding market activity in the company's  common  stock  on
Friday, April 19.   The  company has issued a press release stating that it
knows of no other corporate  developments, aside from the matters involving
Dr. Abuchowski's parting with  the Company, which would explain the trading
activities in the company's common stock on Friday, April 19.




                            SIGNATURES


     Pursuant to the requirements  of  the Securities Exchange Act of 1934,

the Registrant has duly caused this report  to  be  signed on its behalf by

the undersigned hereunto duly authorized.




Dated:  April 23, 1996




                                               ENZON, INC.
                                             (Registrant)

                                   By:   /S/JOHN A. CARUSO
                                         John A. Caruso
                                         Vice President,
                                         Business Development and
                                         General Counsel